LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LUCD LUCID DIAGNOSTICS INC.

Post-Mkt 12-22 16:14:20 EST

1.13

+0.01

+0.89%

盘后1.12

-0.01-0.88%

16:13 EST

High1.14	Low1.11	Vol349.92K
Open1.11	D1 Closing1.12	Amplitude2.68%
Mkt Cap155.07M	Tradable Cap108.67M	Total Shares137.23M
T/O394.53K	T/O Rate0.36%	Tradable Shares96.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LUCD","market":"US","secType":"STK","nameCN":"LUCID DIAGNOSTICS INC.","latestPrice":1.13,"timestamp":1766437200000,"preClose":1.12,"halted":0,"volume":349918,"hourTrading":{"tag":"盘后","latestPrice":1.12,"preClose":1.13,"latestTime":"16:13 EST","volume":7171,"amount":8103.2092041,"timestamp":1766438013097},"delay":0,"floatShares":96168400,"shares":137227495,"eps":-0.786597,"marketStatus":"Post-Mkt","change":0.01,"latestTime":"12-22 16:14:20 EST","open":1.11,"high":1.14,"low":1.11,"amount":394526.946312,"amplitude":0.026786,"askPrice":1.13,"askSize":3,"bidPrice":1.1,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-0.786597,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766451600000},"marketStatusCode":4,"adr":0,"listingDate":1634184000000,"exchange":"NASDAQ","adjPreClose":1.12,"preHourTrading":{"tag":"盘前","latestPrice":1.12,"preClose":1.12,"latestTime":"09:29 EST","volume":1763,"amount":2021.469904,"timestamp":1766413799045},"postHourTrading":{"tag":"盘后","latestPrice":1.12,"preClose":1.13,"latestTime":"16:13 EST","volume":7171,"amount":8103.2092041,"timestamp":1766438013097},"volumeRatio":0.354204},"requestUrl":"/m/hq/s/LUCD","defaultTab":"news","newsList":[{"id":"2589884858","title":"Lucid Diagnostics Files for Mixed Shelf of up to $175 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2589884858","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589884858?lang=en_us&edition=fundamental","pubTime":"2025-12-06 06:04","pubTimestamp":1764972247,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0TF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","LUCD"],"gpt_icon":0},{"id":"2584944800","title":"Lucid Diagnostics (LUCD) Receives a Buy from Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2584944800","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584944800?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:26","pubTimestamp":1763558801,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Ross Osborn from Cantor Fitzgerald reiterated a Buy rating on Lucid Diagnostics, with a price target of $3.00. The ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lucid-diagnostics-lucd-receives-a-buy-from-cantor-fitzgerald-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lucid-diagnostics-lucd-receives-a-buy-from-cantor-fitzgerald-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","BK4099","LCID","BK4082","BK4596","LUCD","BK4555"],"gpt_icon":0},{"id":"2583462534","title":"Lucid Diagnostics Reports Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583462534","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583462534?lang=en_us&edition=fundamental","pubTime":"2025-11-13 12:39","pubTimestamp":1763008780,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics Inc. ( ($LUCD) ) has released its Q3 earnings. Here is a breakdown of the information Lucid Diagnostics Inc. presented to its inv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4555","LCID","BK4099","BK4551","BK4596","BK4082","LUCD"],"gpt_icon":0},{"id":"2582372579","title":"Lucid Diagnostics Gains Medicare Support for EsoGuard","url":"https://stock-news.laohu8.com/highlight/detail?id=2582372579","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582372579?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:51","pubTimestamp":1762955460,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics ( ($LUCD) ) has issued an update. Lucid Diagnostics reported its third-quarter 2025 financial results, highlighting the processin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-gains-medicare-support-for-esoguard?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-gains-medicare-support-for-esoguard?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","BK4099","BK4555","LUCD","LCID","BK4082","BK4596"],"gpt_icon":0},{"id":"2573952129","title":"Lucid Diagnostics Inc. Files Initial Beneficial Ownership Statement for Director John R. Palumbo","url":"https://stock-news.laohu8.com/highlight/detail?id=2573952129","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573952129?lang=en_us&edition=fundamental","pubTime":"2025-10-08 04:46","pubTimestamp":1759869976,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing discloses that John R. Palumbo, serving as a director of the company, holds a beneficial ownership in Lucid Diagnostics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 07, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL5v6Wc3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","PAVM","LUCD"],"gpt_icon":0},{"id":"2570923580","title":"Press Release: Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2570923580","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570923580?lang=en_us&edition=fundamental","pubTime":"2025-09-25 20:01","pubTimestamp":1758801660,"startTime":"0","endTime":"0","summary":"Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors. NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  , a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. , today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025.\"John is a highly accomplished executive whose 40 years of healthcare leadership experience spans early-stage ventures, growth-stage companies, and Fortune 100 corporations,\" said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. \"His vast experience and deep expertise--which includes guiding early-stage companies through commercial growth--and vast network will be of great value as we approach transformational commercial milestones.\". Prior to that, he held senior executive roles at AmerisourceBergen Corporation , where he led the Provider business u","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4555","R","BK4585","XBI","HCSG","BK4588","BK4596","BK4551","LUCD","BK4022","NQmain","BK4232","BK4082","LCID","BK4099","BK4137","PAVM","BK4581","XLV"],"gpt_icon":0},{"id":"2567102132","title":"Press Release: Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2567102132","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567102132?lang=en_us&edition=fundamental","pubTime":"2025-09-16 20:01","pubTimestamp":1758024060,"startTime":"0","endTime":"0","summary":"Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones--including Medicare coverage for EsoGuard--and to accelerate commercial coverage expansion. NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  , a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. , today announced the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs, reporting to the Chief Executive Officer. Ms. Scelfo is widely recognized in the diagnostics industry as an accomplished health policy leader with more than 25 years of strategic and operational experience across market access, reimbursement, and government affairs. She will oversee Lucid's rapidly expanding market access and reimbursement activities, focused on payor engagement and securing broad insurance coverage and patient access to its EsoGuard Esophageal DNA Test.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4099","BK4551","BK4555","LCID","BK4022","BK4596","R","LUCD","BK4082","PAVM"],"gpt_icon":0},{"id":"2566464989","title":"Analysts Conflicted on These Healthcare Names: Lucid Diagnostics (LUCD) and Sanofi (OtherSNYNF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2566464989","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566464989?lang=en_us&edition=fundamental","pubTime":"2025-09-12 09:40","pubTimestamp":1757641211,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lucid Diagnostics (LUCD – Research Report) and Sanofi (SNYNF – Re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-lucid-diagnostics-lucd-and-sanofi-othersnynf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-lucid-diagnostics-lucd-and-sanofi-othersnynf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4007","LCID","BK4555","LUCD","BK4099","SNYNF","HCSG","BK4082","BK4596","BK4551"],"gpt_icon":0},{"id":"2566999025","title":"Lucid Diagnostics Closes Roughly $26.9 Million Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2566999025","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566999025?lang=en_us&edition=fundamental","pubTime":"2025-09-11 21:53","pubTimestamp":1757598832,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics  said Thursday it closed an underwritten public offering of around 28.8 million common shares, including about 3.8 million shares issued under the full exercise of the overallotment option.The company said it expects total net proceeds to be around $26.9 million, which its intends to use for working capital and general corporate purposes.Price: 1.03, Change: +0.01, Percent Change: +0.98","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LUCD","BK4551","BK4099","BK4555","BK4082","BK4596"],"gpt_icon":1},{"id":"2566999325","title":"Lucid Diagnostics Inc. Files Prospectus Supplement for Common Stock Offering, Raising Approximately $26.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2566999325","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566999325?lang=en_us&edition=fundamental","pubTime":"2025-09-11 21:28","pubTimestamp":1757597298,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics Inc., a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc., has announced the closing of an underwritten public offering of 28,750,000 shares of its common stock at a price of $1.00 per share. This includes the full exercise of the underwriters' option to purchase an additional 3,750,000 shares. The offering is expected to yield net proceeds of approximately $26.9 million after expenses. The company plans to utilize these funds for working capital and general corporate purposes. Canaccord Genuity LLC and BTIG, LLC served as joint bookrunners, with Maxim Group LLC acting as co-manager. The securities were offered under a shelf registration statement declared effective by the SEC on December 6, 2022. The prospectus supplement and accompanying base prospectus were filed with the SEC on September 10, 2025. Copies of the prospectus are available from Canaccord Genuity LLC and BTIG, LLC.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL59BNwn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD","BK4082","PAVM"],"gpt_icon":0},{"id":"2566998594","title":"Lucid Diagnostics Price Target Maintained With a $2.50/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2566998594","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566998594?lang=en_us&edition=fundamental","pubTime":"2025-09-11 00:44","pubTimestamp":1757522640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LUCD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 10, 2025 12:44 ET (16:44 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD"],"gpt_icon":0},{"id":"2566983434","title":"BUZZ-U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2566983434","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566983434?lang=en_us&edition=fundamental","pubTime":"2025-09-11 00:05","pubTimestamp":1757520303,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen EnergyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nL6N3UX0RB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKE","GLSI","TLN","HAL","EQT","LEA","CHWY","BW","APA","GEV","LUCD","TRML","NVDD","PBPB","ALNY","RNA","ACHC","PMVP","AME","RAL","FANG","NEM","NVDU","DRMA","RKT","CVX","FITB","ASST","TVTX","BWA","JOBY","WALD","AMLX","VST","CEG","SNPS","HPQ","XOM","DHR","DNTH"],"gpt_icon":1},{"id":"2566601552","title":"Lucid Diagnostics Shares Fall After Pricing of Public Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2566601552","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566601552?lang=en_us&edition=fundamental","pubTime":"2025-09-10 21:00","pubTimestamp":1757509200,"startTime":"0","endTime":"0","summary":"Shares of Lucid Diagnostics fell after its secondary offering of common shares priced.Its stock slid 17.3% to $1.05 in premarket trading on Wednesday.The cancer-prevention medical diagnostics company said its underwritten public offering of 25 million shares was priced at $1 apiece.Lucid also said it granted underwriters a 30-day option to purchase up to an additional 3.75 million common shares at the public offering price, excluding underwriting discounts and commissions.The offering is expected to close on Thursday.The company, which is a unit of PAVmed Inc., said it would use the gross proceeds of $25 million for working capital and general corporate purposes.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD","BK4099","BK4596","BK4555","BK4082","BK4551"],"gpt_icon":1},{"id":"2566606239","title":"BUZZ-Lucid Diagnostics slides on $25 mln stock sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2566606239","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566606239?lang=en_us&edition=fundamental","pubTime":"2025-09-10 20:29","pubTimestamp":1757507376,"startTime":"0","endTime":"0","summary":"BUZZ-Lucid Diagnostics slides on $25 mln stock sale**  Shares of Lucid Diagnostics LUCD.O down 18.1% at $1.04 premarket after $25 mln follow-on prices** New York City-based cancer prevention firm announces selling 25 mln shares at $1** Offering price represents ~21% discount to stock's last close** The PAVmed Inc PAVM.O subsidiary plans to use net proceeds for working capital, general purposes** Canaccord Genuity and BTIG are joint bookrunners for the offering** Lucid has ~108.5 mln shares outstanding for $138 mln market cap** Its flagship product, the EsoGuard Esophageal DNA Test, is used to screen for esophageal precancer and cancer in at-risk gastroesophageal reflux disease patients** Through Tues, shares gained 55% YTD** All 6 analysts are bullish on LUCD and median PT is $3, per LSEG","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nL6N3UX0LO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD","BK4082","PAVM"],"gpt_icon":0},{"id":"2566051366","title":"Lucid Diagnostics Announces Pricing of Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2566051366","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566051366?lang=en_us&edition=fundamental","pubTime":"2025-09-10 20:00","pubTimestamp":1757505616,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nTUA4RXQP6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LUCD","BK4082","PAVM"],"gpt_icon":0},{"id":"2566646431","title":"Lucid Diagnostics Plans Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2566646431","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566646431?lang=en_us&edition=fundamental","pubTime":"2025-09-10 05:50","pubTimestamp":1757454605,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics  said late Tuesday it plans an underwritten public offering of its shares.The company said it also plans to grant its underwriters a 30-day option to buy additional shares.Proceeds will be used for working capital and general corporate purposes, Lucid said.Shares were down over 11% during after-hours trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LUCD","BK4099","BK4596","BK4082","BK4555","BK4551"],"gpt_icon":0},{"id":"2566481806","title":"BRIEF-Lucid Diagnostics Announces Proposed Public Offering Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2566481806","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566481806?lang=en_us&edition=fundamental","pubTime":"2025-09-10 04:08","pubTimestamp":1757448508,"startTime":"0","endTime":"0","summary":"BRIEF-Lucid Diagnostics Announces Proposed Public Offering Of Common StockSept 9 (Reuters) - Lucid Diagnostics Inc LUCD.O:LUCID DIAGNOSTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCKSource text: ID:nPn4VdKHxaFurther company coverage: LUCD.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nTUA2CTWNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","LUCD","PAVM"],"gpt_icon":0},{"id":"2565404554","title":"Lucid Diagnostics Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2565404554","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565404554?lang=en_us&edition=fundamental","pubTime":"2025-09-05 18:41","pubTimestamp":1757068860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LUCD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 05, 2025 06:41 ET (10:41 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD"],"gpt_icon":0},{"id":"2562957735","title":"BRIEF-Pavmed Signs Letter Of Intent To License Groundbreaking Endoscopic Esophageal Imaging Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2562957735","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562957735?lang=en_us&edition=fundamental","pubTime":"2025-08-26 20:04","pubTimestamp":1756209874,"startTime":"0","endTime":"0","summary":"BRIEF-Pavmed Signs Letter Of Intent To License Groundbreaking Endoscopic Esophageal Imaging TechnologyAug 26 (Reuters) - Lucid Diagnostics Inc LUCD.O:PAVMED SIGNS LETTER OF INTENT TO LICENSE GROUNDBRE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nFWN3UI054:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","BK4082","LUCD"],"gpt_icon":1},{"id":"2562735592","title":"PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2562735592","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562735592?lang=en_us&edition=fundamental","pubTime":"2025-08-26 20:01","pubTimestamp":1756209680,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nFWN3UI054:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAVM","BK4082","LUCD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.luciddx.com","stockEarnings":[{"period":"1week","weight":-0.0345},{"period":"1month","weight":0.098},{"period":"3month","weight":0.0275},{"period":"6month","weight":-0.1111},{"period":"1year","weight":0.4528},{"period":"ytd","weight":0.368}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.066778},{"month":2,"riseRate":0.75,"avgChangeRate":0.154261},{"month":3,"riseRate":0.5,"avgChangeRate":-0.101745},{"month":4,"riseRate":0.5,"avgChangeRate":-0.092654},{"month":5,"riseRate":0.5,"avgChangeRate":0.04431},{"month":6,"riseRate":0.25,"avgChangeRate":-0.075357},{"month":7,"riseRate":0.5,"avgChangeRate":0.031793},{"month":8,"riseRate":0.75,"avgChangeRate":0.032951},{"month":9,"riseRate":0.25,"avgChangeRate":-0.178841},{"month":10,"riseRate":1,"avgChangeRate":0.186111},{"month":11,"riseRate":0.4,"avgChangeRate":-0.040647},{"month":12,"riseRate":0.2,"avgChangeRate":-0.148764}],"exchange":"NASDAQ","name":"LUCID DIAGNOSTICS INC.","nameEN":"LUCID DIAGNOSTICS INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LUCID DIAGNOSTICS INC.(LUCD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LUCID DIAGNOSTICS INC.,LUCD,LUCID DIAGNOSTICS INC.股票,LUCID DIAGNOSTICS INC.股票老虎,LUCID DIAGNOSTICS INC.股票老虎国际,LUCID DIAGNOSTICS INC.行情,LUCID DIAGNOSTICS INC.股票行情,LUCID DIAGNOSTICS INC.股价,LUCID DIAGNOSTICS INC.股市,LUCID DIAGNOSTICS INC.股票价格,LUCID DIAGNOSTICS INC.股票交易,LUCID DIAGNOSTICS INC.股票购买,LUCID DIAGNOSTICS INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LUCID DIAGNOSTICS INC.(LUCD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}